Clinical trial
Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals…
NCT00393224 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00393224 |
|---|---|
| Title | Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families |
| Official title | Defining Markers of Susceptibility to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Study type | Observational |
| Conditions | Nasopharyngeal Neoplasms |
| Enrollment | 952 |
| Start date | Jul 5, 2005 |
| Primary completion | Jun 2, 2020 |
| Completion | Jun 2, 2020 |
| First posted | Oct 27, 2006 |
| Last update posted | Jun 4, 2020 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: